Pan-KRAS Inhibitor LY4066434

**Semantic type:** Pharmacologic Substance

**Definition:** An orally bioavailable non-covalent inhibitor that targets the oncogenic KRAS wild-type (WT) and various KRAS mutant forms, including KRAS G12D, G12V, G12C, G13D, G12A, and G12S, with potential antineoplastic activity. Upon oral administration, pan-KRAS Inhibitor LY4066434 selectively targets and binds to KRAS, thereby inhibiting KRAS-dependent signaling. This inhibits the growth and survival of KRAS-overexpressing and mutated tumor cells. KRAS, a member of the RAS family of oncogenes, plays an important role in cell signaling, division and differentiation. Mutations of KRAS may induce constitutive signal transduction leading to tumor cell growth, proliferation, invasion, and metastasis.

**Synonyms:** - KRAS Inhibitor LY4066434 - LY 4066434 - LY-4066434 - LY4066434